Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.52 |
| ▸ | STAT3 | P40763 | 16/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29426190 | 0.95 | STAT3 (0.49) | POLBCTDSP1STAT3MAPTMEN1 | |
| SCHEMBL29425801 | 0.90 | MAPT (0.49) | POLBCTDSP1STAT3MAPTMEN1 | |
| SCHEMBL31179905 | 0.85 | POLB (0.51) | POLBCTDSP1STAT3MAPTMEN1 | |
| SCHEMBL29426020 | 0.85 | POLB (0.51) | POLBCTDSP1STAT3MAPTMEN1 | |
| Phloyoside I SCHEMBL29426051 | 0.84 | POLB (0.55) | POLBCTDSP1STAT3MAPTMEN1 | |
| Phlomiol SCHEMBL9057941 | 0.84 | POLB (0.55) | POLBCTDSP1STAT3MAPTMEN1 | |
| SCHEMBL29425860 | 0.81 | ALDH1A1 (0.49) | POLBCTDSP1STAT3MAPTMEN1 | |
| Sesamoside SCHEMBL26561978 | 0.80 | POLB (0.52) | POLBCTDSP1STAT3MAPTMEN1 | |
| SCHEMBL30782246 | 0.80 | POLB (0.51) | POLBCTDSP1STAT3MAPTMEN1 | |
| SCHEMBL26597978 | 0.80 | POLB (0.51) | POLBCTDSP1STAT3MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110475768-B | Plant extract rich in desquamation-field sesamin derivatives as immunosuppressant for treating immune diseases | 疼痛制药实验室股份有限公司 | 2023-12-01 | — | — | CN | disclosed |
| EP-4001270-A1 | PLANT EXTRACTS ENRICHED WITH IPOLAMIIDE DERIVATIVES AS IMMUNOSUPPRESSANTS FOR TREATING IMMUNOLOGICAL DISORDERS AND VITILIGO | Aché Laboratórios Farmacêuticos S.A. (BR) | 2022-05-25 | — | — | EP | disclosed |
| EP-4001270-A1 | PLANT EXTRACTS ENRICHED WITH IPOLAMIIDE DERIVATIVES AS IMMUNOSUPPRESSANTS FOR TREATING IMMUNOLOGICAL DISORDERS AND VITILIGO | Aché Laboratórios Farmacêuticos S.A. (BR) | 2022-05-25 | — | — | EP | disclosed |
| EP-3583103-B1 | PLANT EXTRACTS ENRICHED WITH IPOLAMIIDE DERIVATIVES AS IMMUNOSUPPRESSANTS FOR TREATING IMMUNOLOGICAL DISORDERS | ACHE LABORATORIOS FARMACEUTICOS SA (BR) | 2022-01-12 | — | — | EP | disclosed |
| EP-3583103-B1 | PLANT EXTRACTS ENRICHED WITH IPOLAMIIDE DERIVATIVES AS IMMUNOSUPPRESSANTS FOR TREATING IMMUNOLOGICAL DISORDERS | ACHE LABORATORIOS FARMACEUTICOS SA (BR) | 2022-01-12 | — | — | EP | disclosed |
| US-20200231561-A1 | PLANT EXTRACTS ENRICHED WITH IPOLAMIIDE DERIVATIVES AS IMMUNOSUPPRESSANTS FOR TREATING IMMUNOLOGICAL DISORDERS | ACHE LABORATORIOS FARMACEUTICOS S.A. (BR) | 2020-07-23 | — | — | US | disclosed |
| CN-110475768-A | The plant extracts rich in ipolamiide derivative as immunosuppressant treatment immunological diseases | ACHE LABORATORIOS FARMACEUTICOS SA | 2019-11-19 | — | — | CN | disclosed |
| WO-2018148816-A4 | PLANT EXTRACTS ENRICHED WITH IPOLAMIIDE DERIVATIVES AS IMMUNOSUPPRESSANTS FOR TREATING IMMUNOLOGICAL DISORDERS | ACHÉ LABORATÓRIOS FARMACÊUTICOS S.A. (BR) | 2019-01-03 | — | — | WO | disclosed |
| WO-2018148816-A3 | PLANT EXTRACTS ENRICHED WITH IPOLAMIIDE DERIVATIVES AS IMMUNOSUPPRESSANTS FOR TREATING IMMUNOLOGICAL DISORDERS | ACHÉ LABORATÓRIOS FARMACÊUTICOS S.A. (BR) | 2018-10-18 | — | — | WO | disclosed |
| WO-2018148816-A2 | COMPOUNDS, PROCESS OF PRODUCTION OF COMPOUNDS, ENRICHED EXTRACT, ENRICHED EXTRACT ACTIVE FRACTIONS, ENRICHED EXTRACT PROCESS OF PRODUCTION, METHOD FOR SELECTING VEGETAL BIOMASS FOR ENRICHED EXTRACT PRODUCTION, COMPOSITION AND USE FOR TREATMENT OF IMMUNOLOGICAL DISORDERS | ACHÉ LABORATÓRIOS FARMACÊUTICOS S.A. (BR) | 2018-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200231561-A1 | PLANT EXTRACTS ENRICHED WITH IPOLAMIIDE DERIVATIVES AS IMMUNOSUPPRESSANTS FOR TREATING IMMUNOLOGICAL DISORDERS | IP6K3, IP6K1, IP6K2 | POLB 4068/4885CTDSP1 4831/4885STAT3 4499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.